

Resource Summary Report

Generated by [NIF](#) on Sep 13, 2026

Panc 02.03

RRID:CVCL_1633

Type: Cell Line

Proper Citation

RRID:CVCL_1633

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1633

Proper Citation: RRID:CVCL_1633

Description: Cell line Panc 02.03 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:9612602](#), [PMID:18000365](#), [PMID:20037478](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Johns Hopkins University School of Medicine; Baltimore; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Panc 02.03

Synonyms: PANC-02-03, Panc_02_03, Panc02.03, Panc 2.03, Panc2.03, Panc2_03, PANC 203, Panc203, PANC203, PANC0203, Panc0203

Cross References: CLO:CLO_0008374, EFO:EFO_0006466, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2553, BioGRID_ORCS_Cell_line:491, BioSample:SAMN03473181, BioSample:SAMN10987714, cancercellines:CVCL_1633, Cell_Model_Passport:SIDM01139, ChEMBL-

Cells:CHEMBL3307761, ChEMBL-Targets:CHEMBL612584, Cosmic:2009528, Cosmic:2434088, Cosmic-CLP:1298475, DepMap:ACH-000042, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298475, GEO:GSM206527, GEO:GSM621891, GEO:GSM887494, GEO:GSM888576, GEO:GSM1024405, GEO:GSM1374810, GEO:GSM1670331, IARC_TP53:28226, LiGeA:CCLE_407, LINCS_LDP:LCL-1739, PharmacDB:Panc02_03_1239_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_1633, PubChem_Cell_line:CVCL_1633, Wikidata:Q54937512

ID: CVCL_1633

Record Creation Time: 20220427T221408+0000

Record Last Update: 20260913T005715+0000

Ratings and Alerts

No rating or validation information has been found for Panc 02.03.

No alerts have been found for Panc 02.03.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. *Cell*, 189(6), 1731.

Zhang H, et al. (2026) Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. *Cell reports. Medicine*, 7(2), 102545.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. *Cell reports. Medicine*, 7(4), 102688.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. *Cell reports*, 45(5), 117314.

Lyubetskaya A, et al. (2026) In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment. *Cell reports*, 45(1), 116827.

Bandi DSR, et al. (2026) ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. *bioRxiv : the preprint server for*

biology.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. *Cell reports*, 45(2), 116956.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. *Science advances*, 11(42), eadx0632.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradar of the Nuclear Pore Complex. *Cancer discovery*, 15(12), 2505.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. *Cancer cell*, 43(8), 1512.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. *iScience*, 28(8), 113149.

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. *Nature communications*, 16(1), 10733.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. *Cell reports*, 38(2), 110236.

Banh RS, et al. (2020) Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. *Cell*, 183(5), 1202.